u/akavaev

ASCO 2026 data showed 72.7% objective response rate in squamous NSCLC and 63.6% in nonsquamous, with low severe toxicity (4.7% immune-related adverse events). FDA fast track potential via PFS endpoint change. The market has not priced in the magnitude of this data; a gap up Monday is expected, followed by institutional upgrades (UBS $135 PT). Short-dated and medium-dated call options offer asymmetric upside. Author is heavily long BNTX options across June/July/September expiries, betting on an immediate catalyst-driven rally and continued positive momentum from deep oncology pipeline. Phase 3 data could fail or show inferiority to Keytruda; safety signals (bleeding events) could re-emerge; overall survival data may disappoint if FDA insists on OS endpoint; market sentiment shift away from biotech.